Achieve Life Sciences, Inc.

XNASHealth care

Last traded price · USD

$7.00

+0.29%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $6.98
Volume: 560
Day's high: —
Day's low: —

In brief

Achieve Life Sciences, Inc. is a health care company listed on Nasdaq, valued at about $722M.
Its shares closed at $6.98 on 4 Nov 2026, up 45.1% over the past year.
From India you can buy ACHV in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Achieve Life Sciences, Inc. (ACHV) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ACHV share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ACHV options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

13.8 days to cover short interest
17.8M shares were sold short at the 15 Oct 2026 settlement, 17.3% of the 102.9M shares outstanding; covering them would take 13.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: −0.7% (SPY −1.6%, XLV +13.5%). 3 months: +4.8% (SPY −0.4%, XLV +15.5%). 1 year: +45.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ACHV, SPY and XLV · as of 4 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $6.98 was 5.4% below its 50-day average ($7.38) and 23.4% above its 200-day average ($5.66). It has closed above the 200-day for 141 sessions, since 16 Apr 2026. The 50-day average crossed above the 200-day on 11 May 2026, 123 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
72% of the way up its 52-week range
Closed at $6.98 on 4 Nov 2026: 19.2% below the 52-week high of $8.64 (3 Sep 2026) and 166.4% above the low of $2.62 (30 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.7%

6 months+45.4%

1 year+45.1%

5 years−22.1%

Newswire

About

Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Website

Notable moves

October 17, 2025
+36.36%
June 27, 2025
−36.47%
December 12, 2023
−42.20%

Achieve Life Sciences, Inc.

XNASHealth care

Last traded price · USD

$7.00

+0.29%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $6.98
Volume: 560
Day's high: —
Day's low: —

In brief

Achieve Life Sciences, Inc. is a health care company listed on Nasdaq, valued at about $722M.
Its shares closed at $6.98 on 4 Nov 2026, up 45.1% over the past year.
From India you can buy ACHV in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Achieve Life Sciences, Inc. (ACHV) shares from India?

Do I need the price of a whole ACHV share to invest?

How much can I invest in US stocks in a year?

Can I trade ACHV options or futures?

Insights

Quotes run fifteen minutes behind.

13.8 days to cover short interest
17.8M shares were sold short at the 15 Oct 2026 settlement, 17.3% of the 102.9M shares outstanding; covering them would take 13.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: −0.7% (SPY −1.6%, XLV +13.5%). 3 months: +4.8% (SPY −0.4%, XLV +15.5%). 1 year: +45.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ACHV, SPY and XLV · as of 4 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $6.98 was 5.4% below its 50-day average ($7.38) and 23.4% above its 200-day average ($5.66). It has closed above the 200-day for 141 sessions, since 16 Apr 2026. The 50-day average crossed above the 200-day on 11 May 2026, 123 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
72% of the way up its 52-week range
Closed at $6.98 on 4 Nov 2026: 19.2% below the 52-week high of $8.64 (3 Sep 2026) and 166.4% above the low of $2.62 (30 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.7%

6 months+45.4%

1 year+45.1%

5 years−22.1%

Newswire

About

Website

Notable moves

October 17, 2025
+36.36%
June 27, 2025
−36.47%
December 12, 2023
−42.20%

Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. in brief

13.8 days to cover short interest

Ahead of SPY and its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

72% of the way up its 52-week range

Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. in brief

13.8 days to cover short interest

Ahead of SPY and its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

72% of the way up its 52-week range